LBA
SPRY icon

Letko, Brosseau & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Letko, Brosseau & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
40,050
+15,350
+62% +$132K ﹤0.01% 93
2026
Q1 		$198K Hold
24,700
– – ﹤0.01% 92
2025
Q4 		$288K Hold
24,700
– – ﹤0.01% 86
2025
Q3 		$248K Hold
24,700
– – ﹤0.01% 88
2025
Q2 		$431K Hold
24,700
– – 0.01% 76
2025
Q1 		$311K Hold
24,700
– – 0.01% 76
2024
Q4 		$261K Hold
24,700
– – 0.01% 89
2024
Q3 		$358K Hold
24,700
– – 0.01% 88
2024
Q2 		$210K Sell
24,700
-11,300
-31% -$100K ﹤0.01% 93
2024
Q1 		$368K Hold
36,000
– – 0.01% 87
2023
Q4 		$197K Hold
36,000
– – ﹤0.01% 88
2023
Q3 		$136K Buy
+36,000
New +$236K ﹤0.01% 90

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Letko, Brosseau & Associates's SPRY Position: Q2 2026 in Review

Letko, Brosseau & Associates increased its ARS Pharmaceuticals (SPRY) stake by 62% in Q2 2026, buying an estimated $132K and bringing the position to 40,050 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #93.

Letko, Brosseau & Associates first reported a position in SPRY in Q3 2023 and has held it in 12 quarters since. The position peaked at $431K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Letko, Brosseau & Associates held 40,050 shares of ARS Pharmaceuticals worth $321K as of Q2 2026.
  • Letko, Brosseau & Associates bought 15,350 ARS Pharmaceuticals shares in Q2 2026, an estimated $132K.
  • ARS Pharmaceuticals made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #93 holding.
  • Letko, Brosseau & Associates first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Letko, Brosseau & Associates's ARS Pharmaceuticals position peaked at $431K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.